Xoma zeroes in on diabetes - and a partnership? - again

Research was on the chopping block as Xoma Corp. looked to cut costs over the past year. But now, even as takeover talk touches the Berkeley antibody drug developer, Xoma may be showing it was wise to cut elsewhere. In a paper published in the May issue of the journal Diabetes, Xoma unveiled a preclinical antibody drug, called XMetA, that targets diabetes. Initial reaction: Diabetes? Really?